US 8,895,008 B2 · Compositions and methods relating to anti-IGF-1 receptor antibodies

Abstract

The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Claims9

Dependent claims

A method of decreasing binding of IGF-1 and IGF-2 to human IGF-1R in a subject in need thereof, comprising administering to said subject an isolated anti-IGF-1R antibody, or an isolated antigen-binding fragment thereof, wherein said antibody or fragment comprises a light chain variable region and a heavy chain variable region, and wherein:

a. said light chain variable region comprises the amino acid sequence of SEQ ID NO:32;
and said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:136;
or
b. said light chain variable region comprises:
i. the CDR 1 sequence of residues 24 through 39 of SEQ ID NO:32;
and
ii. the CDR 2 sequence of residues 55 through 61 of SEQ ID NO:32;
and
iii. the CDR 3 sequence of residues 94 through 102 of SEQ ID NO:32;
and said heavy chain variable region comprises:
i. the CDR 1 sequence of residues 31 through 36 of SEQ ID NO:136;
and
ii. the CDR 2 sequence of residues 51 through 66 of SEQ ID NO:136;
and
iii. the CDR 3 sequence of residues 99 through 108 of SEQ ID NO:136.

12 more elements

Dependencies are inferred from the claim text.

Compositions and methods relating to anti-IGF-1 receptor antibodies

Life of this patent

Compositions and methods relating to anti-IGF-1 receptor antibodies

Life of this patent

Abstract

Claims9